Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland
|
|
- Hortense Boyd
- 5 years ago
- Views:
Transcription
1 Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Thanks for material provided by Marlieke de Kraker & Andrew Stewardson!
2 Antibiotic resistance: global public health concern Tackling drug-resistant infections globally (O Neill report) - Mai 2016
3
4 What are clinical implications of antimicrobial resistance? Treatment failure due to wrong choice Increased morbidity and mortality Use of more toxic, more expensive and less efficacious therapeutic alternatives Added burden of nosocomial infections Risk of explosive outbreaks
5 Main Conclusions: - Antibiotic resistance significantly impacts on illness burden in the community. - Patients with laboratory-confirmed antibiotic-resistant urinary and respiratory-tract infections are more likely to experience delays in clinical recovery after treatment with antibiotics.
6 Deadly MRSA Infection C. H. (71) first woman elected lieutenant governor in South Dakota. She had suffered a spinal fracture and 3 broken ribs Oct. 8 while sailing the Adriatic Sea. She underwent surgery in Zagreb, Croatia on Oct. 10, then was hospitalized Oct. 19 during a stop in Switzerland on her way back to the US. She suffered pneumonia, a bacterial blood infection, and a series of strokes, which claimed her life in Lausanne, Switzerland on October 25, 2007.
7 Acinetobacter Outbreak, Lausanne Index patient Severe burn injuries, transfer from Bali (Oct 2002) Multi-R Acinetobacter at admission Outbreak Spread to 2 patients 6 months later: 6 new cases Closure of the burn unit Environnement Widespread contamination: 16/161 (10%) positive swabs Patients Environnement Environmental cleaning & disinfection Complete replacement of all disposable material Zanetti G et al. Infect Control Hosp Epidemiol 2007; 28:
8
9 Economic burden of MDROs Increased direct costs of providing care to MDRO-infected patients; Indirect costs to patients, caregivers, & diminished quality of life; Infrastructure and productivity costs of surveillance, screening and isolation; Antibiotic treatment costs for therapy or empiric coverage of MDRO
10
11
12 Projected impact of antimicrobialresistant neonatal sepsis in India
13 Apocalypse soon?
14
15 Add Raoult, CID headline AMR burden
16
17 Public health burden of drug resistance C.E. Phelps, Med Care 1989; 27: The estimates of the burden caused by bacterial resistance depend heavily on unknown parameters. US General Accounting Office, 1999 Report to U.S. Congress Data are insufficient to determine full extent of public health burden associated with antibacterial resistance.
18 Affected people / deaths R. Rappuoli. Nat Med From Pasteur to genomics: progress and challenges in infectious diseases
19 Threat level: URGENT
20 Threat level: SERIOUS
21
22 Tackling drug-resistant infections globally (O Neill report) - Mai 2016
23
24 Usability/Business case, O Neill report General objective for the AMR review group: Defining the steps needed to avoid the AMR crisis Objective of this report: Determine the health and macro-economic consequences for the world, especially in emerging economies if antimicrobial resistance is not tackled Tackling drug-resistant infections globally (O Neill report) - Mai 2016
25 De Kraker N, Stewardson A, Harbarth S. PLoS Med 2016; 13: e
26 Caveats Accurate, with and without random error Internal validity? External validity? Assumptions? Peer review? In-accurate, with and without random error De Kraker N, Stewardson A, Harbarth S. PLoS Med 2016; 13: e
27 Estimating the Burden of Disease (BoD) Related to Antimicrobial Resistance Number of infections (I) Resistance proportions (R) Burden measure: Attributable mortality proportion (M) BoD= I*R*M Future scenarios Determine coefficient for change (c) Future BoD = I*c1 * R*c2 *M*c3 De Kraker N, Stewardson A, Harbarth S. PLoS Med 2016; 13: e
28 Number of infections (BoD= I*R*M) EARS-net data: Representativeness? Mainly tertiary care hospitals Few community/paediatric/ltcf isolates ECDC, EARS-Net Antimicrobial resistance surveillance report 2013/2014
29 Number of sets/1,000 pds Resistance proportions (BoD= I*R*M) EARS-net and WHO data: Representativeness? Highly variable blood culture rates ECDC, EARS-Net Antimicrobial resistance surveillance report 2012/2011*/2009**/2008***/2006
30 Extrapolation from bloodstream infections to infections at other sites Fifteen Brooklyn hospitals ESBL+ K. pneumoniae isolates 12 BSIs, 4 SSIs, 14 UTIs, 14 LRTIs: Infect Control Hosp Epidemiol 2002; 23: : 0.33 : 1.2 : bed hospital in Spain MRSA isolates 4 BSIs, 17 SSIs, 3 UTIs, 5 LRTIs: 1 : 4.3 : 0.8 : 1.3 Infect Control Hosp Epidemiol 2006; 27:
31 Attributable mortality (BoD= I*R*M) ECDC, The bacterial challenge: Time to react 2009
32 Methodological challenges -- Why is it so difficult to estimate the attributable mortality of AMRrelated infection?
33 Problem 1: - Severity of illness and underlying disease
34 PROBLEM High crude mortality in patients with infections caused by multidrug-resistant bacteria Carriers of multiresistant bacteria who die in the hospital may die either with simple asymptomatic carriage of resistant bacteria with infection by resistant bacteria or because of infection (primary cause of death)
35 Problem 2: - Appropriateness of antimicrobial therapy
36 Causal pathways & challenges Severity of underlying illness Resistant infection Death Appropriateness of antibiotics
37 Mortality prediction in nosocomial bacteremia Severity of underlying illness: RR = Bacteremia Death Inappropriate antibiotic therapy RR = McCabe & Jackson. Arch Intern Med. 1962;110: Freeman J et al. Rev Infect Dis 1988; 10:
38 Problem 3: - Timing of events and time-varying exposures
39 The importance of correct measurement When did the antibiotic-resistant infection occur? Non-infected Discharge Infected Admission infection Death
40 Cohort study, countries, 537 ICUs, pts Sophisticated statistical analyses adjusted for the timing of events and competing outcomes (multistate modelling) Lambert et al. Lancet Infect Dis 2011
41 Main findings High excess mortality associated with bacteremia and pneumonia acquired in the intensive care unit Substantially increased excess length of stay for pneumonia, but not for bloodstream infection Pseudomonas aeruginosa: greatest burden (not MRSA) AMR: only a small contribution to the overall burden of ICUacquired infections Lambert et al. Lancet Infect Dis 2011
42 Multicenter study (TIMBER) Population Patients with bloodstream infection (BSI) caused by S. aureus or Enterobacteriaceae Main exposure of interest Methicillin resistance or third-generation cephalosporin resistance Main comparison group Patients with infections by susceptible strains Main outcomes Excess length of stay (LoS) and in-hospital mortality = Extended-spectrum betalactamase-producing Enterobacteriaceae (ESBL-E) (e.g. E.coli, Klebsiella spp) Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
43 Methods Design: Multicentre retrospective cohort study 10 European hospitals Population: All acute inpatient admissions January 2010 December 2011 Data collection: Demographic, clinical, microbiologic & administrative data were extracted electronically One investigator from each site trained in standardized data collection during a workshop Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
44 Statistical methods Cox proportional hazards analysis Compute hazards of inpatient mortality Multivariable models Baseline covariates: for age, sex, elective versus emergent admission, previous hospitalisation, 17 comorbidities Time-varying covariates: bloodstream infection, ICU admission or surgery Multistate modeling Compute excess hospital LoS (days) attributable to each type of BSI Accounting for competing risks (discharge vs death) Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
45 Outcomes (unadjusted) S. aureus analysis Group N Incidence proportion (events/100 admissions) Total length of stay Median (IQR) Mortality Count (%) MRSA BSI (16 45) 36 (22.1%) MSSA BSI (13 39) 149 (16.8%) Non-infected (2 7) (1.7%) Enterobacteriaceae analysis Group n Incidence proportion (events/100 admissions) Total length of stay Median (IQR) Mortality Count (%) 3GCR-E BSI ( ) 58 (16.1%) 3GCS-E BSI (7 28) 212 (10.1%) Non-infected (2 7) (1.7%) 62 Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
46 In-hospital mortality Adjusted proportional hazards analysis Interpretation: Risk of death after bloodstream infection (BSI) Adjusted for age, sex, emergent/elective admission, comorbidities, nights hospitalised in previous 12 months, plus ICU-admission and surgical procedures as time-dependent covariates 63 Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
47 Excess length-of-stay Multistate model 64 Stewardson A,., Harbarth S. EuroSurveillance 2016; 21: 33
48
49 Assumptions for future scenarios KPMG report, the global economic impact of anti-microbial resistance 2014
50 Number of death certificates in England & Wales mentioning MRSA Office for National Statistics online 2010
51 The way forward Comprehensive, population-based antimicrobial resistance surveillance Paediatric & geriatric infections Community-acquired infections Low-, middle-, and high-income countries Different types of infections Morbidity and mortality data Accurate & valid analyses
52
53 Summary Preventing antimicrobial resistance is desirable by patients and society Consistency of data regarding the impact of antimicrobial resistance on clinical outcomes and risk of treatment failure However: Paucity of data regarding the overall impact of antimicrobial resistance on health services and societal burden, especially in LMIC Due to methodological limitations, we may have overestimated the attributable mortality and excess costs of antimicrobial resistance 83
54 Situation in people dying due to antibiotic resistance? Methodological challenges & flaws of these projections: To predict total number of infections To predict the proportion of resistance To predict the attributable mortality Lack of robust data note of caution: broad brush estimates, not certain forecasts De Kraker N, Stewardson A, Harbarth S. PLoS Med 2016; 13: e
55 What will happen in 2050? The first Rhino will be born on the North pole Geneva will be renamed Genève-sur-Mer Ivanka Trump, the 1 st female US president, will be re-elected for the 4 th time in a row people will die from AMR Courtesy: Marc Bonten (Utrecht)
56 Thanks for your attention!
57 Basic Copyright Notice & Disclaimer 2018 This presentation is copyright protected. All rights reserved. You may download or print out a hard copy for your private or internal use. You are not permitted to create any modifications or derivatives of this presentation without the prior written permission of the copyright owner. This presentation is for information purposes only and contains non-binding indications. Any opinions or views expressed are of the author and do not necessarily represent those of Swiss Re. Swiss Re makes no warranties or representations as to the accuracy, comprehensiveness, timeliness or suitability of this presentation for a particular purpose. Anyone shall at its own risk interpret and employ this presentation without relying on it in isolation. In no event will Swiss Re be liable for any loss or damages of any kind, including any direct, indirect or consequential damages, arising out of or in connection with the use of this presentation.
Why should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationClinical and Economic Impact of Urinary Tract Infections Caused by Escherichia coli Resistant Isolates
Clinical and Economic Impact of Urinary Tract Infections Caused by Escherichia coli Resistant Isolates Katia A. ISKANDAR Pharm.D, MHS, AMES, PhD candidate Disclosure Katia A. ISKANDAR declare to meeting
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationBurden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital
Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity
More informationHand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY
Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY MDROs and Hand Hygiene Guidelines HH Apr14 The Science of Hand Hygiene in Healthcare Settings
More informationThe importance of infection control in the era of multi drug resistance
Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationWHO Surgical Site Infection Prevention Guidelines. Web Appendix 4
WHO Surgical Site Infection Prevention Guidelines Web Appendix 4 Summary of a systematic review on screening for extended spectrum betalactamase and the impact on surgical antibiotic prophylaxis 1. Introduction
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationThe surgical site infection risk in developing countries. Yves BUISSON Société de Pathologie Exotique
The surgical site infection risk in developing countries Yves BUISSON Société de Pathologie Exotique Surgical site infections Health-care-associated infections occurring within 30 days after surgery, or
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More informationAntibiotic Stewardship in the Hospital Setting
Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationGet Smart For Healthcare
Get Smart For Healthcare Know When Antibiotics Work Marry Bardin, Quality Improvement Advisor June 9, 2015 Why We Need to Improve In-patient Antibiotic Use Antibiotics are misused in hospitals Antibiotic
More informationANTIMICROBIAL RESISTANCE
Sunday, February 22, 2015 1 Abdullah M Assiri ANTIMICROBIAL RESISTANCE Local perspectives Abdullah M. Assiri, MD Assistant Deputy Minister for Preventive Medicine MOH, KSA Global threat The WHO Global
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationWHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health
New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries 30 APRIL 2014 GENEVA - A new report by WHO its first to look at antimicrobial resistance,
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationNational Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing Wales. HCAI and AMR Programme
National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing 2017 Wales HCAI and AMR Programme The Healthcare Associated Infection and Antimicrobial Resistance
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationSurveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe
Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe Carl Suetens, ECDC Presented by Håkan Hanberger ecdc.europa.eu Message/Questions from C Suetens to Workshop 7, MIE2009
More informationWhat s happening across the UK with antimicrobial prescribing quality indicators?
What s happening across the UK with antimicrobial prescribing quality indicators? Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Antimicrobial Management Team Network
More informationSurveillance of Multi-Drug Resistant Organisms
Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More informationImpact of NHS England Quality Indicators on Antimicrobial Resistance. Professor Alan Johnson National Infection Service Public Health England
Impact of NHS England Quality Indicators on Antimicrobial Resistance Professor Alan Johnson National Infection Service Public Health England A Risk Assessment of Antibiotic Pan-Drug Resistance in the UK:
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information11/22/2016. Hospital-acquired Infections Update Disclosures. Outline. No conflicts of interest to disclose. Hot topics:
Hospital-acquired Infections Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationImpact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital
Impact of Antimicrobial Resistance on Human Health Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital AMR in Foodchain Conference, UCD, Dec 2014 Sir Patrick Dun s Hospital
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationDr Nata Menabde Executive Director World Health Organization Office at the United Nations Global action plan on antimicrobial resistance
Global action plan on antimicrobial resistance Dr Nata Menabde Executive Director World Health Organization Office at the United Nations Proportion of MDR among previously treated TB cases, 1994-2010 0-
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationRise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University
Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies
More informationSurveillance of AMR in PHE: a multidisciplinary,
Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International
More informationBirgit Ross Hospital Hygiene University Hospital Essen Essen, Germany. Should we screen for multiresistant gramnegative Bacteria?
Birgit Ross Hospital Hygiene University Hospital Essen Essen, Germany Should we screen for multiresistant gramnegative Bacteria? CONCLUSIONS: A program of universal surveillance, contact precautions,
More informationReducing nosocomial infections and improving rational use of antibiotics in children in Indonesia
Yemeni International Congress on Infectious Disease (YICID), 2014 Reducing nosocomial infections and improving rational use of antibiotics in children in Indonesia Background and rationale Study of a multifaceted
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationLindsay E. Nicolle University of Manitoba Winnipeg, CANADA
Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Long Term Care Facilities: Spectrum low acuity assisted living mobile independent Not LTAC high acuity complete functional disability dialysis
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationThe challenge of growing resistance
EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More information9.4 Antimicrobial Resistance
9.4 Antimicrobial Resistance a) Key Pathogens causing Bloodstream Infections 2016 Summary Estimated 99% coverage of the Irish population versus 97% in 2015 There were 3,057 reports of invasive E. coli
More informationBacterial infections complicating cirrhosis
PHC www.aphc.info Bacterial infections complicating cirrhosis P. Angeli, Dept. of Medicine, Unit of Internal Medicine and Hepatology (), University of Padova (Italy) pangeli@unipd.it Agenda Epidemiology
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES
ANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES 1 Crisis: Antibiotic Resistance Success Strategy 2 OBJECTIVES Discuss
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationDr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust
Dr Eleri Davies Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust Antimicrobial stewardship What is it? Why is it important? Treatment and management of catheter-associated
More informationEpidemiology of early-onset bloodstream infection and implications for treatment
Epidemiology of early-onset bloodstream infection and implications for treatment Richard S. Johannes, MD, MS Marlborough, Massachusetts Health care-associated infections: For over 35 years, infections
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives John Jernigan, MD, MS Alex Kallen, MD, MPH Division of Healthcare Quality Promotion Centers for Disease
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationHEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE
Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!
More informationThe Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
More informationAntibiotic Resistance in India
Antibiotic Resistance in India Sumanth Gandra MD, MPH Center for Disease Dynamics, Economics & Policy July 5, 2017 AMR Cross Council Initiative Challenges and Opportunities Workshop, Heathrow Disclaimer/Disclosures
More informationAntibiotic resistance: how did we get here and what can we do? Peter Lambert LHS
Antibiotic resistance: how did we get here and what can we do? Peter Lambert LHS How do we diagnose and treat infection? Organisms are cultured and identified Microscopy gives a clue to identity Staphylococcus
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More informationAntimicrobial Resistance Update for Community Health Services
Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs
More information(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE
(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement
More informationDr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune
Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1 Anti microbial resistance is now a global geometrically increasing threat
More informationEpidemiology and Economics of Antibiotic Resistance
Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking
More informationHospital ID: 831. Bourguiba Hospital. Tertiary hospital
Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationMDRO in LTCF: Forming Networks to Control the Problem
MDRO in LTCF: Forming Networks to Control the Problem Suzanne F. Bradley, M.D. Professor of Internal Medicine Division of Infectious Disease University of Michigan Medical School VA Ann Arbor Healthcare
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION The Staphylococci are a group of Gram-positive bacteria, 14 species are known to cause human infections but the vast majority of infections are caused by only three of them. They
More informationEFSA s activities on Antimicrobial Resistance
EFSA s activities on Antimicrobial Resistance CRL-AR, Copenhagen 23 April 2009 Annual Workshop of CRL - AR 1 Efsa s Role and Activities on AMR Scientific advices Analyses of data on AR submitted by MSs
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationKeeping Antibiotics Working: Nursing Leadership in Action
Keeping Antibiotics Working: Nursing Leadership in Action Pat McLaine, DrPH, MPH, RN Robyn Gilden, PhD, RN Department of Family and Community Health Maryland Nurses Association October 2016 US 2 million
More informationMeropenem for all? Midge Asogan ICU Fellow (also ID AT)
Meropenem for all? Midge Asogan ICU Fellow (also ID AT) Infections Common reason for presentation to ICU Community acquired - vs nosocomial - new infection acquired within hospital environment Treatment
More information